# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Brian Cheng maintains Intellia Therapeutics (NASDAQ:NTLA) with a Overweight and lowers the price target fr...
RBC Capital analyst Luca Issi maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target fr...